DE3872333T2 - Doxazosin als antiatherosklerotikum. - Google Patents

Doxazosin als antiatherosklerotikum.

Info

Publication number
DE3872333T2
DE3872333T2 DE8888305069T DE3872333T DE3872333T2 DE 3872333 T2 DE3872333 T2 DE 3872333T2 DE 8888305069 T DE8888305069 T DE 8888305069T DE 3872333 T DE3872333 T DE 3872333T DE 3872333 T2 DE3872333 T2 DE 3872333T2
Authority
DE
Germany
Prior art keywords
doxazosin
atherosclerosis
aortic
acid addition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888305069T
Other languages
German (de)
English (en)
Other versions
DE3872333D1 (de
Inventor
Archie Calhoun Swindell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Original Assignee
Pfizer Corp Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of DE3872333D1 publication Critical patent/DE3872333D1/de
Publication of DE3872333T2 publication Critical patent/DE3872333T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8888305069T 1987-08-26 1988-06-03 Doxazosin als antiatherosklerotikum. Expired - Lifetime DE3872333T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/089,716 US4758569A (en) 1987-08-26 1987-08-26 Doxazosin as an anti-atherosclerosis agent

Publications (2)

Publication Number Publication Date
DE3872333D1 DE3872333D1 (de) 1992-07-30
DE3872333T2 true DE3872333T2 (de) 1992-12-03

Family

ID=22219243

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888305069T Expired - Lifetime DE3872333T2 (de) 1987-08-26 1988-06-03 Doxazosin als antiatherosklerotikum.

Country Status (15)

Country Link
US (1) US4758569A (cg-RX-API-DMAC7.html)
EP (1) EP0305028B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6471817A (cg-RX-API-DMAC7.html)
KR (1) KR910002145B1 (cg-RX-API-DMAC7.html)
AT (1) ATE77552T1 (cg-RX-API-DMAC7.html)
AU (1) AU594880B2 (cg-RX-API-DMAC7.html)
CA (1) CA1323572C (cg-RX-API-DMAC7.html)
DE (1) DE3872333T2 (cg-RX-API-DMAC7.html)
DK (1) DK170499B1 (cg-RX-API-DMAC7.html)
HU (1) HU204196B (cg-RX-API-DMAC7.html)
IE (1) IE60005B1 (cg-RX-API-DMAC7.html)
IL (1) IL86735A (cg-RX-API-DMAC7.html)
MY (1) MY103102A (cg-RX-API-DMAC7.html)
NZ (1) NZ225053A (cg-RX-API-DMAC7.html)
ZA (1) ZA884237B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DE69327128T2 (de) * 1992-04-01 2000-04-20 Pfizer, Inc. Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
JP2002536325A (ja) * 1999-02-05 2002-10-29 ナイトロシステムズ アイエヌシー 疾患を治療するためのｌ−アルギニン基盤の処方およびその使用方法
AU6951601A (en) 2000-07-13 2002-01-30 Takeda Chemical Industries Ltd Lipid-rich plaque inhibitors
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
JP2006515765A (ja) 2002-11-15 2006-06-08 エスディージーアイ・ホールディングス・インコーポレーテッド 滑膜性関節を治療するためのコラーゲンベース材料および方法
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4361564A (en) * 1978-11-30 1982-11-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
US4532135A (en) * 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
US4582832A (en) * 1984-10-09 1986-04-15 Pfizer Inc. Trimazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
IL86735A0 (en) 1988-11-30
NZ225053A (en) 1997-02-24
KR890003379A (ko) 1989-04-14
ATE77552T1 (de) 1992-07-15
MY103102A (en) 1993-04-30
DK170499B1 (da) 1995-10-02
EP0305028A2 (en) 1989-03-01
AU594880B2 (en) 1990-03-15
AU1752988A (en) 1989-03-02
US4758569A (en) 1988-07-19
CA1323572C (en) 1993-10-26
IE60005B1 (en) 1994-05-18
DK313688A (da) 1989-02-27
JPS6471817A (en) 1989-03-16
EP0305028A3 (en) 1990-03-14
IE881695L (en) 1989-02-26
KR910002145B1 (ko) 1991-04-06
DE3872333D1 (de) 1992-07-30
DK313688D0 (da) 1988-06-09
ZA884237B (en) 1990-02-28
JPH0575729B2 (cg-RX-API-DMAC7.html) 1993-10-21
HUT51141A (en) 1990-04-28
HU204196B (en) 1991-12-30
IL86735A (en) 1994-05-30
EP0305028B1 (en) 1992-06-24

Similar Documents

Publication Publication Date Title
DE3872333T2 (de) Doxazosin als antiatherosklerotikum.
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69835245T2 (de) Pharmazeutische Kombinationen von Amlodipin und Atorvastatin
DE69636783T2 (de) Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration
DE69735598T2 (de) Progesterone zur behandlung oder minderung von ischemie in menopause befindlichen frauen, die östrogen bekommen
DE69829097T2 (de) Cholesterinsenkende Zusammensetzung enthaltend Coenzym Q
DE69734405T2 (de) Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
DE69822295T2 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE3639378C2 (cg-RX-API-DMAC7.html)
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE3343934A1 (de) M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels
DE69330680T2 (de) Verwendung von 17 Alpha - Dihydroequilenin zur Senkung des Cholesterinspiegels
DE69202162T2 (de) Verwendung von Tenidap zur Senkung des Gesamtserumcholesterins, LDL-Cholesterins und Triglyceride.
DE69501421T2 (de) Hematetrenome Derivat als antiarteriosklerotisches Mittel
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE3875324T2 (de) Dl-5-((2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidin-2,4-dion als antiatherosklerosemittel.
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE69327128T2 (de) Hydroxylierte Metaboliten und Derivate von Doxazosin gegen Atherosklerose
DE69710258T2 (de) Mittel zur Beschleunigung des Tränenflusses enthaltend einen Serotonin-Liganden, insbesondere Aminoalkoxybibenzyle
DE2161588C3 (de) Mittel zur Behandlung von Hyperlipoproteinämien
EP0002803B1 (de) Cis-(3,3,5)-Trimethylcyclohexanol zur Verwendung bei der Behandlung von Galleleiden
DE3518559A1 (de) Neue verwendung von dihydroergotamin
DE3406837A1 (de) Arteriosklerose-arzneimittel und -prophylaktikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition